Functional Mystacial Pad Allograft Tolerance Induced and Maintained by Vascularized Bone Marrow Transplant.

C.-H. Lin,^1,2 M. Anggelia,^1,2 C.-J. Wen,¹ W.-Y. Chuang,³ H.-Y. Cheng,¹ C.-H. Lin,^1,2 G. Brandacher.⁴

¹Department of PRS, Center for Vascularized Composite Allotransplantation, Chang Gung Memorial Hospital, Taoyuan, Taiwan
²Chang Gung Medical College and Chang Gung University, Taoyuan, Taiwan
³Department of Pathology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
⁴Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2017 American Transplant Congress

Abstract number: C292

Keywords: Alloantigens, Bone marrow, FK506, Nerve allografts

Session Information

Session Name: Poster Session C: Tolerance/Immune Regulation

Session Type: Poster Session

Date: Monday, May 1, 2017

Session Time: 6:00pm-7:00pm

Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Background: Accumulating findings indicate that vascularized bone marrow (VBM) transplantation plays a critical role to promote tolerance of vascularized composite allografts (VCA) without life-long immunosuppression. We hypothesize that VBM may induce secondary rat mystacial pad allograft tolerance and functional outcome can be restored.

Method: Thirty transplants includes VBM allografts, mystacial pad allografts, and sequential VBM and mystacial pad allografts from Brown-Norway (BN) rats were performed onto Lewis (Lew) rats and antilymphocyte serum (ALS) followed by 7 days (D) of 2mg/kg/day of Tacrolimus (Tac) and 3mg/kg/day for 3 weeks (W) of rapamycin (RPM) were administered. Long-term allograft survival, donor-specific tolerance as well as chimerism level were evaluated. A secondary full-thickness skin transplant from both BN and Sprague-Dawley (SD) strains was performed when the vascularized hind-limb transplant survived >90 days.

Results: Under ALS and combination of short-term Tac and RPM treatment, animals received VBM showed long-term graft survival (>120 days) with chimerism persisted for 30 days but then declined long-term. Tolerant rats showed CD3⁺ T cells donor-specific hyporesponsiveness and tolerance to donor-specific skin graft, but not to allo third-party skin grafts. Interestingly, in the animals received same immunosuppressive regimen, long-term mystacial pad graft tolerance was only maintained in the presence of VBM (MST >90 days vs MST= 70 days). Moreover, those animals presented good whiskering and functional recovery.

Conclusion: Efficacy of VBM transplantation to induce long-term secondary mystacial pad allograft survival has been shown in this study. Mystacial pad allograft in which nerves were repaired showed functional recovery.

CITATION INFORMATION: Lin C.-H, Anggelia M, Wen C.-J, Chuang W.-Y, Cheng H.-Y, Lin C.-H, Brandacher G. Functional Mystacial Pad Allograft Tolerance Induced and Maintained by Vascularized Bone Marrow Transplant. Am J Transplant. 2017;17 (suppl 3).

To cite this abstract in AMA style:

Lin C-H, Anggelia M, Wen C-J, Chuang W-Y, Cheng H-Y, Lin C-H, Brandacher G. Functional Mystacial Pad Allograft Tolerance Induced and Maintained by Vascularized Bone Marrow Transplant. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/functional-mystacial-pad-allograft-tolerance-induced-and-maintained-by-vascularized-bone-marrow-transplant/. Accessed May 9, 2025.

« Back to 2017 American Transplant Congress